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a  b  s  t  r  a  c  t
Accurate  determination  of  in  vitro  biological  activity  of therapeutic  erythropoietin  is  essential  in qual-
ity control  of  recombinant  human  erythropoietin  (rHuEPO)  pharmaceutical  products.  However,  most  of
currently-used  methods  leave  much  to  be desired  so  that  a simpler,  quicker  and more  accurate  method  is
urgently  needed.  The  bioassay  described  here  utilizes  a sub  clone  of  UT-7/epo  cell  line  stably  transfected
with  luciferase  gene  under  the  control  of sis inducible  element  and  interferon  -activated  sequence  ele-
ment promoter.  Active  erythropoietin  could  induce  the  expression  of  luciferase  by  signaling  through
the  erythropoietin  receptor  and  the  dose-response  curve  showed  good  linearity,  yielding  a coefﬁcient  of
determination  of  0.99  or higher.  The  optimized  assay  was simpler  with  the  operation  completed  within
24  h  and  more  sensitive  with  EC50 being  0.077  IU/mL.  The  accuracy  estimates  ranged  from  81.7%  to  102.4%,
and  both  intra-assay  and  inter-assay  precision  was  below  15.0%.  The  robustness  of the assay  was  demon-eporter gene assay strated  by no effect  of passage  levels  of  the  cells  on  the performance  of  the  assay  (p values:  0.772  for
sample  1 and  0.943  for sample  2). Besides,  Bland–Altman  analysis  showed  a high  consistency  of  the new
assay  with  in vivo  reticulocyte  assay  in  results.  These  results  suggested  that  the  new  reporter  gene  assay
can  be a viable  supplement  to  the  traditional  reticulocyte  assay  and  employed  in  potency  determination
of  rHuEPO  pharmaceutical  products.
© 2014  The  Authors.  Published  by Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY-NC-SA. Introduction
Erythropoietin (EPO) is mainly secreted by the kidney and
nvolved in the growth and maturation of erythroid cells from
recursors. Decreased bioactive production of EPO could result in
nemia [1–3]. Since recombinant human erythropoietin (rHuEPO)
as successfully developed in the 1980s, it has been widely used in
he treatment of anemia caused by chronic kidney disease, blood
oss anemia, and myelodysplasia induced by chemoradiotherapy
f cancer as the ﬁrst hematopoietic growth factor applied clinically
4–7].
Accurate determination of in vivo and in vitro biological activ-
ties of therapeutic EPO is crucial to quality control of rHuEPO
harmaceutical products [8,9]. In vivo bioactivity of EPO is closely
elated to its serum half-life, which is dependent on carbohy-
rate structure, especially on the number of sialic acid residues
∗ Corresponding author. Tel.: +86 1067014382; fax: +86 1067018094.
E-mail address: wangjz nifdc2014@163.com (J. Wang).
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ttp://dx.doi.org/10.1016/j.jpba.2014.08.003
731-7085/© 2014 The Authors. Published by Elsevier B.V. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-sa/3.0/).
at the termini of the tri- and tetra-antennary sugar chains
[10,11]. Traditional 59Fe incorporation assay is considered the gold
standard assay for EPO, but the procedure has such drawbacks
as the use of a radioisotope and elaborate animal preparation
[8]. Recently, reticulocyte assay based on the proliferation of
reticulocytes in normocythemic mice has been widely applied in
standardization studies and potency evaluation of rHuEPO pharma-
ceutical preparations [12,13]. In vitro bioassay could estimate EPO’s
receptor-activating ability that is associated with the protein struc-
ture of EPO molecules [14]. The various in vitro bioassays that have
been developed so far, including immunoassays, afﬁnity assays
and cell proliferation assays, have some limitations: immunoassays
and afﬁnity assays can conﬁrm nothing more than antigenic sites
and binding activities respectively while cell proliferation assays
such as murine 32D cell line, NFS60, TF1, UT-7 and UT-7/EPO usu-
ally require extended experimental cycles [15–19]. Considering the
huge market demand for rHuEPO products, a more accurate and
convenient in vitro assay needs to be explored to facilitate the rapid
batch release of rHuEPO formulations.
The reporter gene assay (RGA) has been increasingly used
to determine the bioactivities of cytokines based on their
der the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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ndividual signal pathway for its simplicity, reliability and high efﬁ-
iency [20–23]. EPO signal pathway has been extensively explored
ver the past decades. It has been conﬁrmed that EPO works by
inding to its receptor EpoR which will undergo a conformational
hange that activates Janus kinase 2 (JAK2). The activated JAK2
ill in turn activate tyrosine phosphorylation of signal transducer
nd activator of transcription 5 (STAT5) that will bind to the sis
nducible element (SIE) and the interferon -activated sequence
GAS) element, activate the expression of downstream genes and
nally promote erythropoiesis [24–26]. But till today, there has
een no report on the potency determination of EPO based on its
ignal pathway using RGA.
In this report, a novel RGA for EPO was developed based on a
T-7/epo cell line stably transfected with luciferase gene under the
ontrol of SIE and GAS promoter. The new RGA was optimized and
ully validated in accordance with the Guidelines of the Interna-
ional Conference on Harmonization (ICH) using good laboratory
ractices (GLPs), followed by comparison with in vivo reticulocyte
ssay in terms of results.
. Materials and methods
.1. Reagents
IMDM (12440), RPMI 1640 (11835) and fetal bovine serum
10099) were purchased from Gibco, Bright Glo luciferase assay
eagent (E2620) from Promega, and hygromycin B (K547) from
mersco.
.2. RHuEPO and other cytokines
National Standard for rHuEPO was obtained from National
tandardization Study Center of Pharmaceutical and Biologi-
al Products. RHuEPO products and other cytokines including
ecombinant human growth hormone (rhGH), recombinant
uman epidermal growth factor(rhEGF), recombinant human
asic ﬁbroblast growth factor(rhBFGF), interferon -2a(IFN-
a), interleukin-11(IL-11), interleukin-2(IL-2), recombinant human
ranulocyte colony-stimulating factor(rhG-CSF) and recombinant
uman granulocyte-macrophage colony-stimulating factor(rhGM-
SF) were provided by different manufacturers. All rHuEPO
roducts used in this study were produced in Chinese hamster
vary cells.
.3. Construction of the reporter gene vector pGL4-SG-Luc
PGL4.26 vector (Promega) contains a minimal promoter
ollowed by a luciferase gene. Three tandem repeats of
onsensus SIE (5′-GTCGACATTTCCCGTAAATC-3′) and GAS (5′-
TATTTCCCAGAAAAGGAAC-3′) were sequentially connected and
nserted into the multiple cloning site of pGL4.26 vector and the
ositive clone was veriﬁed by DNA sequencing.
.4. Development of UT-7-SG-Luc cells stably transfected with
GL4-SG-Luc
The plasmid pGL4-SG-Luc was introduced into UT-7/epo cells
ATCC) by electroporation. Cells were selected beginning at 48 h
fter transfection in selective media (IMDM containing 10% fetal
ovine serum, 1 IU/mL EPO and 500 g/mL hygromycin B). After
bout 4 weeks’ selection, hygromycin-resistant cells were then
loned by limited dilutions to obtain single cell clones and screened
or the induction of luciferase by treating cells with gradient con-
entrations of EPO. After that the positive clones were routinely
aintained in selective media.iomedical Analysis 100 (2014) 316–321 317
2.5. RGA procedure
UT-7-SG-Luc cells were washed three times by phosphate buffer
solution and incubated at 37 ◦C with 5% CO2 in assay medium
(RPMI 1640 containing 5% fetal bovine serum and 10 mM HEPES) for
17–20 h. Cells were then collected and seeded into 96 well Costar
plates, with 6 × 104 cells in the presence of rHuEPO standards or
test samples in a total volume of 100 L per well, followed by incu-
bation at 37 ◦C with 5% CO2 for 4 h. Then 100 L of Promega Bright
Glo Luciferase Assay reagent was added, and the plate was subse-
quently shaken for 5 min  on a titre-plate shaker. Luciferase activity
was ﬁnally determined by a Luminoscan Ascent plate reader.
2.6. Reticulocyte assay for EPO potency determination
Eight-week-old BALB/c mice were allocated to standard and
sample groups in fully randomized order, with 5 mice per treatment
group. The standard and test samples were diluted to appropriate
concentrations with saline containing 0.1% bovine serum albumin.
A single dose of 7.5, 15 or 30 IU EPO/0.2 mL  per mouse was  injected
subcutaneously into the respective animal on day 1. On day 4, blood
was taken from the orbital venous sinus of each mouse and reticulo-
cytes were counted by the Sysmex R-500 Hematology Analyzer. The
study was  approved by the Ethic Committee of National Institute
for Food and Drug Control.
2.7. Speciﬁcity
The speciﬁcity of the RGA was  evaluated by determining
whether the luciferase output could be affected by the presence
of aggregated rHuEPO and other therapeutic cytokines including
rhGH, rhEGF, rhBFGF, IFN-2a, IL-11, IL-2, rhG-CSF and rhGM-CSF.
The aggregated rHuEPOs were prepared by incubating rHuEPO
samples at 90 ◦C for 1 h. All samples were diluted to gradient
concentrations of 10, 2.5, 0.63, 0.16, 0.039, 0.0098, 0.0024 and
0.00061 g/mL in assay medium, and then used to treat the cells
under the same condition as described above for the analyses of
rHuEPO. The levels of luciferase activity were compared to those
obtained with intact rHuEPO treatment.
2.8. Bland–Altman analysis
The agreement between the results of RGA and reticulocyte
assay was evaluated by a Bland-Altman plot. Thirty-four batches
of qualiﬁed rHuEPO injections or powder injections that ranged
from 2500 to 45,000 IU per vial were obtained from different man-
ufacturers. Both assays were performed on each sample, and the
relative potency was calculated respectively, resulting in 68 data
points. Each of the 34 samples was then represented on the graph
by assigning the log-transformed average of two measurements
as the abscissa (x-axis) value, and the ratio of RGA vs. reticulocyte
assay as the ordinate (y-axis) value.
2.9. Statistical analyses
Data analyses of reticulocyte assays were carried out according
to the protocol of Chinese Pharmacopeias by parallel line methods.
A four-parameter logistic model (Section 5.3 of European Pharma-
copoeia) was used to calculate the relative potency, dose response
and linear range for RGA. Statistical techniques for method vali-
dation involved the coefﬁcient of variation (CV), recovery rate,
ANOVA and Bland–Altman plot. Analyses were carried out using
Sigmaplot 12.0 for dose response and linear range determination,
SoftMax Pro software (Molecular Devices, USA) for relative potency
estimation and SPSS 19.0 for method validation.
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Table 1
Optimized parameters for the RGA.
Experiment parameters Optimal values
Cell starvation time 17–20 h
Cell number (per well) 6.0 × 104
Initial concentration of rHuEPO 2 IU/mL
rHuEPO dilution multiple 2
rHuEPO stimulation time 4 h
Sensitivity (EC50) 0.077 IU/mL
Linear range 0.03–1.0 IU/mL
Crucial experiment parameters of the new RGA were optimized, and the optimal
T
P
Tig. 1. Responsiveness of UT-7/G7 cells to rHuEPO. UT-7/G7 cells were treated with
radient concentrations of rHuEPO. Each point and error bar represents the mean
nd standard deviation of three replicates, respectively.
. Results
.1. Response of UT-7/G7 cells to the treatments of rHuEPO
The reporter gene vector pGL4-SG-Luc was successfully con-
tructed and transfected to UT-7/epo cells. Resistant clones were
elected in the presence of hygromycin B, and then subcloned by
imited dilution. As shown in Fig. 1, one of the positive clones was
ound to produce high levels of luciferase in response to rHuEPO
reatment and showed high sensitivity and a dose–response curve
a four-parameter logistic curve) with excellent curve-ﬁtting (R-
quared was 1.0). This clone was then designated as UT-7/G7 cell
ine and employed to establish a reporter gene assay for rHuEPO
roducts.
.2. Optimization of RGA procedure
To obtain stronger reactivity and better sensitivity, crucial
xperiment parameters of RGA were subsequently optimized. UT-
/G7 cells were routinely maintained in the presence of EPO, which
hould be removed before tests to reduce the expression of back-
round luciferase. Our tests found that being washed three times
y phosphate buffer solution and incubated in the absence of EPO
or 17–20 h (starvation time) was sufﬁcient to maintain the sur-
ival of UT-7/G7 cells and low-level expression of background
uciferase. Besides, other parameters including UT-7/G7 cell num-
er, rHuEPO working concentration and stimulation time were also
ptimized. Table 1 summarized the optimal conditions used in all
ubsequent experiments. With the optimal condition, EC50 (50%
able 2
recision of the new RGA.
Sample 1 
Plates Intra-assay CV
1 2 3 
Day 1 3520 3768 4069 7.3 
Day  2 4016 4142 4274 3.1 
Day  3 4008 4335 4693 7.9 
Day  4 3699 3812 4061 4.8 
Day  5 3740 4057 3888 12.1 
Mean  3797 4023 4197 – 
Inter-assay CV (%) 5.6 5.9 7.4 – 
wo rHuEPO pharmaceutical products were tested by RGA and their respective potenciesconditions used in all subsequent experiments were listed in the table as well as the
sensitivity and linear range of the assay.
effective concentration) was  0.077 IU/mL and the linear range was
0.03–1.0 IU/mL.
3.3. Method validation of RGA
To validate the new RGA, two rHuEPO pharmaceutical products,
injection for sample 1 and powder injection for sample 2, were
tested in triplicates for each dose and their respective potency was
estimated using the National Standard for rHuEPO as a reference
for activity. All tests were conducted according to ICH Guidelines,
including precision, accuracy, speciﬁcity and robustness.
3.3.1. Precision
In order to determine the precision of the new RGA, we  ran
the assay on ﬁve different days, with three repeated analyses of
rHuEPO products each day. Such design made it possible to bet-
ter understand the plate-to-plate variability as well as inter-assay
variation. As shown in Table 2, our analyses resulted in intra-assay
(within-day) CV of 3.1% to 14.0% and inter-assay (between-day)
CV of 4.8% to 7.4%. The linear range (logarithmic phase) of all
dose–response curves ran almost parallel to each other, indicating
that each group behaved nearly indistinguishably (data not shown).
Besides, ANOVA suggested no statistically signiﬁcant day effect (P
values: 0.255 and 0.615 for sample 1 and sample 2, resp.).
3.3.2. Accuracy
The accuracy was evaluated applying the new method to the
analyses of the in-house mixture of the rHuEPO formulations with
known amounts of rHuEPO standard preparation. The accuracy
was calculated as the percentage of rHuEPO standard recovered
from rHuEPO formulations according to Chinese Pharmacopeias.
The experiment consisted of six repeated assays on different days.
As shown in Table 3, the CV of six potency estimates was less
than 5.0% for both rHuEPO formulations (3.5% and 4.7%, respec-
tively) and the recovery rates were between 81.7% and 102.4%,
Sample 2
 (%) Plates Intra-assay CV (%)
1 2 3
3215 3437 4177 14.0
3675 3879 4085 5.3
3871 3832 4471 8.8
3782 3506 4094 7.8
3847 3761 3931 6.1
3678 3683 4152 –
7.3 5.4 4.8 –
 were estimated using the National Standard for rHuEPO as a reference for activity.
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Fig. 2. Speciﬁcity of the assay. Responsiveness of UT-7/G7 cells to a variety of different cytokines including rhGH, rhEGF, rhBFGF, IFN-2a, IL-11, IL-2, rhG-CSF and rhGM-CSF
as  well as aggregated rHuEPO were detected. Each column illustrates the mean of three replicates.
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iig. 3. Stability of UT-7/G7 cell lines. Sample 1(A) and sample 2(B) were rHuEPO p
ifferent stages (passage # 8, 30, 65) respectively. The graphs depict the linear rang
uciferase output vs. maximal luciferase intensity for each group.
emonstrating that no signiﬁcant interference of matrix formula-
ion was found in this assay.
.3.3. Speciﬁcity of the assay
Since JAK2-SATAT5 signal pathway is not exclusive for EPO,
xperiments were conducted to assess whether the presence of
ther cytokines could affect the expression of luciferase in UT-7/G7
ells. As shown in Fig. 2, none of the eight cytokines except for
HuEPO could inﬂuence the luciferase activities in a wide range
f drug concentrations (0.0006–10 g/mL), and the aggregated
HuEPO showed remarkably reduced activity, suggesting UT-7/G7
ells were speciﬁcally responsive to EPO in this assay.
.3.4. Stability of UT-7/G7 cell line
The stability of UT-7/G7 cell line is crucial to the robustness ofhe new RGA, which was  evaluated by comparing the responsive-
ess of cells at three different stages (passage # 8, 30, 65) to two
HuEPO samples respectively. No signiﬁcant difference was  found
n potency estimates between three different passages (one-wayaceutical products. The analyses of both samples were performed on cells at three
se–response curves. The luciferase activity is represented by the ratio of individual
analysis of variance, P values: 0.772 and 0.943 for sample 1 and
sample 2, respectively) and the CV of three potency estimates from
cells at different stages was 10.0% for sample 1 and 6.6% for sample
2, suggesting no effect of the passage number on responsiveness of
UT-7/G7 cells to EPO. Fig. 3 showed that the cells at different stages
behaved nearly indistinguishably.
3.4. Agreement between RGA test and reticulocyte assay
The agreement between RGA and reticulocyte assay was
assessed using a Bland–Altman plot, which is widely accepted as
a powerful tool to quantify the difference between two methods,
particularly for the analyses of a new method vs. a gold-standard
[27,28]. Given the wide range of drug concentrations, all averages of
the two measurements were log-transformed in Fig. 4. The average
ratio of RGA vs. reticulocyte assay was  0.99 while 95% agreement
limits were between 0.82 and 1.16. As shown in Fig. 4, most of
the points in terms of ratios of RGA to reticulocyte assay were
between 0.82 and 1.16, with only one point out of the range. The
320 Y. Yang et al. / Journal of Pharmaceutical and B
Table  3
Recovery test.
Round Sample 1 Sample 2
Estimated
potency (IU)a
Recovery
rateb (%)
Estimated
potency (IU)
Recovery
rate (%)
1 3874 85.4 3776 89.0
2  3805 95.1 3746 102.4
3  3772 86.6 3833 81.7
4  3675 85.4 3603 82.9
5  3985 96.3 3801 87.8
6  4035 85.4 4142 91.5
Mean 3857.67 – 3564.5 –
CV%  3.5 – 4.7 –
a Estimated potency was  calculated using the National Standard for rHuEPO as a
reference for activity.
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ab Recovery rate was calculated as the percentage of rHuEPO standard recovered
rom rHuEPO formulations according to Chinese Pharmacopeias.
attern remained generally symmetric around the average ratio,
hich was close to one, revealing statistical consistency between
he two methods across a wide range of drug concentrations.
. Discussion
The pharmacological use of rHuEPO has been well established
nd has had a dramatic impact on the quality of life of patients
ith renal disease [5,6]. EPO is a glycoprotein, with approximately
0% of the molecular mass of the mature molecule made up of four
arbohydrate chains (three N-linked and one O-linked). The car-
ohydrate moieties of EPO contain at least 10 molecules of sialic
cid, which is an important determinant of the pharmacokinetic
ehavior of EPO in vivo by preventing degradation and delaying
learance of EPO from circulation [10,11]. The protein structure
f EPO molecules is associated with the receptor-activating abil-
ty of EPO, which is always estimated by in vitro bioassays. Only
hen in vitro bioactivities are consistent with in vivo bioactivi-
ies can the rHuEPO products be used clinically [8]. Since rHuEPOs
roduced in mammalian cells contain multiple isoforms with het-
rogeneous carbohydrate moieties, potency determination of sialic
cid and isoelectric focusing electrophoresis are also essential test
tems in routine quality control of rHuEPO pharmacological prod-
cts (Chinese Pharmacopoeia (2010)).
ig. 4. Bland–Altman plot. Each plot represents the ratio of RGA vs. reticulocyte
ssay against the log-transformed average of the two assays. The upper and lower
otted lines deﬁne the agreement limits within which 95% of differences between
he  two methods are expected to lie, and the middle dotted line represents the
verage ratio of RGA vs. reticulocyte assay.iomedical Analysis 100 (2014) 316–321
On binding to EpoR, EPO could activate several signal pathways
including JAK2-STAT5, Ras-MAPK, JAK2-NF-KappaB, PI3K-ATK and
DAG-PKC. JAK2-STAT5 pathway has been clearly elaborated and
considered to be directly correlated with the bioactivity of EPO
[29,30]. Based on these ﬁndings, two speciﬁc DNA response ele-
ments of STAT5, SIE and GAS and an EPO-dependent cell line
UT-7/epo were chosen to explore a novel bioassay for rHuEPO prod-
ucts.
In this study, a novel RGA was developed employing a UT-7/epo
cell line stably transfected with luciferase gene under the con-
trol of SIE and GAS promoter and subsequently validated for its
precision, speciﬁcity, robustness and agreement with reticulocyte
assay. The constructed UT-7/G7 cell line showed strong reactivity
to rHuEPO and excellent curve-ﬁtting (Fig. 1). The optimized assay
could be completed within 24 h and proved to be more sensitive
with an EC50 of 0.077 IU/mL. Our analyses resulted in both intra-
and inter-assay variation less than 15.0%, and recovery rates ranged
from 81.7% to 102.4%, demonstrating good precision and accu-
racy, which were even better than most of currently-used methods
[8,13]. None of the eight cytokines involved in our study except for
rHuEPO could affect the expression of luciferase in UT-7/G7 cells,
suggesting good speciﬁcity. Data obtained from cells at three differ-
ent stages (passage # 8, 30, 65) showed no statistically signiﬁcant
difference in potency estimates and inter-passage CV values were
found to be below 10%, suggesting no effect of the passage number
on responsiveness to rHuEPO in this assay. Finally, Bland–Altman
analysis suggested that for rHuEPO products with proper carbo-
hydrate structures, the results of RGA were highly consistent with
in vivo bioactivities of rHuEPO [18].
In conclusion, here for the ﬁrst time we  reported a new RGA for
rHuEPO with good speciﬁcity, precision, accuracy and robustness.
The new assay also showed a high consistency with reticulocyte
assay in terms of results. However, it has many advantages over
reticulocyte assay, such as simpler operation, higher efﬁciency and
no need of animal test. This RGA could be used as a viable supple-
ment to reticulocyte assay and employed in potency determination
of rHuEPO pharmaceutical products. Besides, it could also be used in
potency determination of other erythropoiesis-stimulating agents
sharing the same receptor with EPO and in detection of neutralizing
antibodies against therapeutic EPO in clinical serum samples.
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